相关实验视频
Updated: May 11, 2025

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.1K
在AZIN1依赖的聚胺合成加速瘤细胞循环的进展,并损害了在骨髓瘤中效应T细胞的功能
Jiaming Yu1,2, Chuanxia Zhang1,2, Qinkai Zhang3
1Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.
Cell death & disease
|April 17, 2025
概括
增强的聚胺生物合成驱动骨髓瘤的进展和免疫疗法耐药性. 针对这种途径,特别是抗酶抑制剂1 (AZIN1),可以减少瘤生长,并提高T细胞治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 骨髓瘤是一种常见的青少年骨癌,免疫治疗反应不佳.
- 这种阻力背后的机制尚未完全理解.
- 多氨酸对细胞生长和癌症进展至关重要.
研究的目的:
- 研究聚胺生物合成在骨髓瘤进展和免疫疗法耐药性中的作用.
- 探索向聚胺合成作为改善癌症治疗的策略.
主要方法:
- 研究了抑制聚胺合成 (AZIN1敲除) 对骨髓瘤细胞的影响.
- 评估了对瘤细胞活力,增殖和基因表达 (MYC,细胞周期基因,免疫调节因子) 的影响.
- 评估了TCR工程T细胞在抑制聚胺合成后对骨髓瘤的疗效.
主要成果:
- 增强的聚胺生物合成对于骨髓瘤细胞增殖和瘤生长至关重要.
- 抑制聚胺合成 (AZIN1敲除) 显著增加T细胞对骨髓瘤的细胞毒性疗效.
- 降低的聚胺水平导致MYC表达减少,瘤细胞活力下降,以及免疫相关分子的表达改变.
结论:
- AZIN1-聚胺轴是骨髓瘤生长和免疫逃逸的关键驱动因素.
- 准聚胺生物合成是一种有前途的策略,可以增强骨髓瘤的免疫疗法.
- 这项研究为开发针对这种侵袭性癌症的新疗法开辟了新的途径.
相关概念视频
Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Positive Regulator Molecules
105.6K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.6K

